Nyrada Inc

Highlights:

•Brain Injury Program:
-Stroke model study underway with drug well tolerated to date. Efficacy results imminent.
-Walter Reed brain injury study scheduled to commence in 3QFY2024.
-GLP safety and toxicity studies scheduled to commence in 3QFY2024.
-On track for Phase I Clinical trial in 1HFY2025.

•Cholesterol-Lowering Program:
-Ongoing low-cost background works to identify alternative pathways for the Cholesterol Lowering program continuing.

•Sound financial position:
-Cash position of $4.65 million as at 31 December 2023 – equivalent to 2.98 cents per share.
-Research and development costs of $0.90 million.
-Sufficient funding for GLP and Brain Injury program Phase I study preparatory works currently scheduled to commence in 1HFY2025.